Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

dc.contributor.author

Lubrano, Ennio

dc.contributor.author

Chan, Jon

dc.contributor.author

Queiro-Silva, Ruben

dc.contributor.author

Cauli, Alberto

dc.contributor.author

Goel, Niti

dc.contributor.author

Poddubnyy, Denis

dc.contributor.author

Nash, Peter

dc.contributor.author

Gladman, Dafna D

dc.date.accessioned

2022-12-01T19:01:56Z

dc.date.available

2022-12-01T19:01:56Z

dc.date.issued

2022-11

dc.date.updated

2022-12-01T19:01:55Z

dc.description.abstract

Objective

Axial involvement in patients with psoriatic arthritis (PsA) is a common subset of this condition, but a unanimous definition has yet to be established. It has been defined by using different criteria, ranging from the presence of at least unilateral grade 2 sacroiliitis to those used for ankylosing spondylitis (AS), or simply the presence of inflammatory low back pain (IBP). Our aim was to identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA.

Methods

This systematic review is an update of the axial PsA (axPsA) domain of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Results

The systematic review of the literature showed that new biologic and targeted synthetic disease-modifying antirheumatic drug classes, namely interleukin (IL)-17A and Janus kinase inhibitors, could be considered for the treatment of axPsA. This would be in addition to previously recommended treatments such as nonsteroidal antiinflammatory drugs, physiotherapy, simple analgesia, and tumor necrosis factor inhibitors. Conflicting evidence still remains regarding the use of IL-12/23 and IL-23 inhibitors.

Conclusion

Further studies are needed for a better understanding of the treatment of axPsA, as well as validated outcome measures.
dc.identifier

jrheum.220309

dc.identifier.issn

0315-162X

dc.identifier.issn

1499-2752

dc.identifier.uri

https://hdl.handle.net/10161/26295

dc.language

eng

dc.publisher

The Journal of Rheumatology

dc.relation.ispartof

The Journal of rheumatology

dc.relation.isversionof

10.3899/jrheum.220309

dc.title

Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.

dc.type

Journal article

duke.contributor.orcid

Goel, Niti|0000-0001-5869-5157

pubs.begin-page

jrheum.220309

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Rheumatology and Immunology

pubs.publication-status

Published

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
kez338.pdf
Size:
311.58 KB
Format:
Adobe Portable Document Format
Description:
Published version